SGLT2 and RAAS inhibitors each independently reduce the risk of cardiovascular and kidney complications associated with type 2 diabetes and they appear to have synergistic effects when used as combination therapy.21, 22. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.